基于代谢酶与PK-PD模型研究丹酚酸盐注射液与阿司匹林药物相互作用机制:PK-PD试验研究方案
本研究为前瞻性、开放标签、平行分组、单中心临床试验,拟整合药效学与药代动力学(PK-PD)数据,探索丹酚酸盐与阿司匹林联合用药的浓度-效应关系及可能机制。主要结局为不同血药浓度下阿司匹林酯酶和儿茶酚-O-甲基转移酶(COMT)活性的变化,以确定两药联用的PK-PD特征,并分析药物暴露水平与药效学指标的相关性。
要点
- 丹酚酸盐与阿司匹林联用的最佳组合尚未经临床试验确立。
- 主要结局为不同血药浓度下阿司匹林酯酶和COMT活性的变化。
- 采用PK-PD建模描述浓度-效应关系并估算药物药理效力。
核心结论
- 本试验旨在评估丹酚酸盐与阿司匹林联用时药代动力学变化与疗效指标之间的关系,并探讨联合用药治疗冠心病的可能机制。
研究设计与样本
- 前瞻性、开放标签、平行分组、单中心临床试验,整合药效学-药代动力学(PK-PD)数据。
- 所有治疗疗程持续10天,第8、9、10天给药前及第10天给药后5分钟、15分钟、30分钟、45分钟、1小时、2小时、4小时、8小时、12小时和24小时采集血样。
关键数值与推荐
- 主要结局为不同血药浓度下阿司匹林酯酶和儿茶酚-O-甲基转移酶(COMT)活性的变化,以确定丹酚酸盐与阿司匹林联用的PK-PD特征。
- 随后分析药物暴露水平与药效学指标之间的相关性。
临床怎么用
- 为临床合理联合用药提供实验依据,并讨论联合用药治疗冠心病的可能机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary heart disease (CHD) is a common cardiovascular disease accounting for 10-20% mortality by heart disease worldwide. The gold standard treatment to manage CHD is aspirin, which may prevent myocardial infarction and sudden death; however, long-term use of aspirin may increase its side effects. Currently, more and more clinicians are exploring different approaches to use the right combination of medicine to enhance the efficacy and reduce side effects. Salvianolate can significantly inhibit the aggregation and activation of platelets in patients with CHD; however, its optimum combination with western medicine is not established or supported by clinical trial results. METHODS/DESIGN: This trial is a prospectively planned, open-labeled, parallel-grouped, single-centered clinical trial with aggregated pharmacodynamics-pharmacokinetics (PK-PD) data. All treatment courses will last for 10 days and blood sample will be acquired before administration on days 8, 9, and 10, and after administration at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h on day 10. This trial uses PK-PD modeling to provide a description of the concentration-effect relationship and an estimate of pharmacological potency of the medicine. The primary outcome will be changes in aspirin esterase and catechol-o-methyltransferase (COMT) activity at different blood concentrations to determine the PK-PD characteristics of the combination of salvianolate and aspirin, followed by analysis of the correlation between exposure level and pharmacodynamic index of the medicines. DISCUSSION: This trial will aim to evaluate the relationship between changes in the pharmacokinetics and therapeutic effect index in the combined use of salvianolate and aspirin. It also discusses the possible mechanism of medicine combination in the treatment for CHD and provides an experimental basis for a clinically rational medicine combination. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03306550 . Registered on 9 October 2017. ClinicalTrials.gov https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0007D8H&selectaction=Edit&uid=U0003QY8&ts=2&cx=oiuc9g.
引用
- Zhang W, Zhu B, Cao W, et al. Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial. Trials. 2018. PMID: 30217228. doi:10.1186/s13063-018-2861-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。